MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

KemPharm Company Profile (NASDAQ:KMPH)

Consensus Ratings for KemPharm (NASDAQ:KMPH) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.50 (586.75% upside)

Analysts' Ratings History for KemPharm (NASDAQ:KMPH)
Show:
DateFirmActionRatingPrice TargetActions
6/14/2016OppenheimerReiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016RBC CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/15/2015Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for KemPharm (NASDAQ:KMPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/12/2016Q1($0.46)($0.20)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4($0.50)($0.64)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.42)($0.68)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.47)($2.45)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/27/2015Q1($0.49)($2.50)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for KemPharm (NASDAQ:KMPH)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.56)($0.56)($0.56)
Q2 20161($0.59)($0.59)($0.59)
Q3 20161($0.66)($0.66)($0.66)
Q4 20161($0.69)($0.69)($0.69)
(Data provided by Zacks Investment Research)
Dividend History for KemPharm (NASDAQ:KMPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for KemPharm (NASDAQ:KMPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/29/2016Travis C MickleCEOBuy2,450$14.57$35,696.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for KemPharm (NASDAQ:KMPH)
DateHeadline
06/25/16 08:39 AMCovering the Bases on KemPharm Inc (NASDAQ:KMPH): Where is the Stock Going? - Press Telegraph
06/25/16 08:39 AMHow Many KemPharm Inc (NASDAQ:KMPH)'s Analysts Are Bearish? - Press Telegraph
06/24/16 07:28 AMKemPharm Inc (NASDAQ:KMPH) Earnings Glance and Target Price Review - Engelwood Daily
06/23/16 05:13 PMKemPharm, Inc. (KMPH) Current Analyst Ratings - Fiscal Standard
06/23/16 05:13 PMEquity Research and Technical Review on KemPharm Inc (NASDAQ:KMPH) - Press Telegraph
06/15/16 04:52 PMWhy KemPharm Inc (NASDAQ:KMPH) Shares Could Face Some Downside - Small Cap Exclusive (press release)
06/15/16 04:52 PMOppenheimer Analyst Weighs In on Two Falling Biotechs: KemPharm Inc (KMPH), Marinus Pharmaceuticals Inc (MRNS) - Smarter Analyst
06/15/16 04:52 PMKemPharm Inc. (KMPH) Dropped To A New Low After FDA Complete Response Letter - RTT News
06/15/16 09:29 AMKemPharm Inc. (KMPH) Dropped To A New Low After FDA Complete Response Letter
06/14/16 04:40 PMKemPharm Inc. (KMPH) Is Sharply Lower After FDA Complete Response Letter - RTT News
06/14/16 09:41 AMKemPharm Inc. (KMPH) Is Sharply Lower After FDA Complete Response Letter
06/13/16 04:38 PMKemPharm says U.S. FDA does not approve its painkiller - [Reuters] - KemPharm Inc said the U.S. health regulator did not approve its abuse-deterrent version of a painkiller, sending the drug developer's shares down more than 30 pct in extended trade. The U.S. Food and Drug ...
06/13/16 04:33 PMKemPharm Inc. (KMPH) Is Falling After FDA Complete Response Letter
06/13/16 04:33 PMKemPharm (KMPH) Receives FDA Complete Response Letter for Apadaz NDA
06/13/16 03:29 PMFDA Issues Complete Response Letter for Apadaz™ New Drug Application - [at noodls] - CORALVILLE, Iowa, June 13, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today ...
06/09/16 06:09 AMKemPharm Files NDA Amendment Request with FDA for Apadaz™ - [at noodls] - CORALVILLE, Iowa, June 09, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today ...
06/09/16 06:06 AMKEMPHARM, INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits -
06/09/16 05:56 AM6:56 am KemPharm files NDA amendment request with the FDA for Apadaz, an abuse-deterrent product candidate indicated for the short-term management of acute pain -
06/06/16 08:34 AMStock Review and Earnings Check on KemPharm Inc (NASDAQ:KMPH) - HNN
06/06/16 07:28 AMKemPharm to Present Data from Pharmacokinetic Trial for Investigational Prodrug Benzhydrocodone at the 2016 International Conference on Opioids - [at noodls] - CORALVILLE, Iowa, June 06, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today ...
06/05/16 04:50 PMAfter Last Week What Do Analysts Think Of KemPharm, Inc. (KMPH) - Share Trading News
06/03/16 07:37 AMShare Rating Focus on KemPharm Inc (NASDAQ:KMPH) - HNN - Share Rating Focus on KemPharm Inc (NASDAQ:KMPH)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.33 on shares of KemPharm Inc (NASDAQ:KMPH). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus number is ...and more »
06/02/16 05:08 PMNews Sentiment For KemPharm Inc (NASDAQ:KMPH) - Investor Newswire - News Sentiment For KemPharm Inc (NASDAQ:KMPH)Investor NewswireKemPharm Inc (NASDAQ:KMPH) has been given a sentiment score of 0.31 by research firm. Coming to the sentiment scale, the impact score measured on daily basis stands on a 1-100 scale. This score is taken into account to get the probability of 1% stock ...and more »
06/02/16 07:41 AMTarget Price and Stock Performance Rundown for KemPharm Inc (NASDAQ:KMPH) - HNN - Target Price and Stock Performance Rundown for KemPharm Inc (NASDAQ:KMPH)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, KemPharm Inc (NASDAQ:KMPH) shares ...and more »
06/01/16 05:12 PMWhy KemPharm Inc. (NASDAQ:KMPH)'s KP511 Means Good News For Shareholders - Scibility Media - Why KemPharm Inc. (NASDAQ:KMPH)'s KP511 Means Good News For ShareholdersScibility MediaThe other issue that shareholders were asked to either approve or reject by exercising their voting rights was the selection of KemPharm Inc. (NASDAQ: KMPH)'s independent public accountant. On the matter of the public accounted, shareholders ratified ...
05/30/16 05:28 PMKemPharm Inc (KMPH) Earns Buy Rating from RBC Capital - Let Me Know About This - KemPharm Inc (KMPH) Earns Buy Rating from RBC CapitalLet Me Know About ThisKemPharm logo KemPharm Inc (NASDAQ:KMPH)'s stock had its “buy” rating restated by equities research analysts at RBC Capital in a research note issued on Sunday. In related news, CEO Travis C. Mickle acquired 2,450 shares of the firm's stock in a ...and more »
05/25/16 04:27 PMKEMPHARM, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/18/16 05:12 PMKemPharm, Inc. to Host Annual Meeting of Stockholders on Tuesday, May 24, 2016 at 9:00 a.m. ET - [at noodls] - CORALVILLE, Iowa, May 18, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced ...
05/13/16 08:43 AMKEMPHARM, INC Files SEC form 10-Q, Quarterly Report -
05/13/16 12:18 AMEdited Transcript of KMPH earnings conference call or presentation 12-May-16 8:30pm GMT -
05/12/16 04:27 PMKemPharm, Inc. Reports First Quarter 2016 Results - [at noodls] - Recent Clinical Development & Regulatory Highlights: Introduced Apadaz™ as the proprietary name for KP201/APAP FDA Advisory Committees voted 16 to 4 in support of Apadaz approval; voted 18 to 2 against ...
05/12/16 04:18 PMKemPharma reports 1Q loss -
05/12/16 06:07 AMQ1 2016 KemPharm Inc Earnings Release - After Market Close -
05/10/16 07:38 AMKemPharm Receives “Fast Track” Designation for KP511, an Investigational Prodrug of Hydromorphone - [at noodls] - CORALVILLE, Iowa, May 10, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today ...
05/07/16 07:58 AMWhy is Endo International (ENDP) Stock Plunging Today? - Zacks.com - MarketWatchWhy is Endo International (ENDP) Stock Plunging Today?Zacks.comOn Friday, shares of global specialty healthcare company Endo International Plc (ENDP - Analyst Report) are plunging, down over 40% after the company reported disappointing first quarter fiscal 2016 results. Earnings per share came in at $1.08, lagging ...Endo Reports First Quarter 2016 Financial ResultsPR Newswire (press release)How Guidance Sank Endo International24/7 Wall St.Analyst Downgrades: KemPharm Inc, Endo International plc, and FireEye IncSchaeffers Research (blog)all 86 news articles »
03/23/16 01:57 PMKemPharm, Inc. (KMPH) Updated Price Targets - Share Trading News - KemPharm, Inc. (KMPH) Updated Price TargetsShare Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of KemPharm, Inc. (KMPH). The most recent broker reports which have been released note that 2 analysts have a rating of ...and more »
03/19/16 12:04 PMKEMPHARM, INC Financials -
03/16/16 05:07 AMKEMPHARM, INC Files SEC form 10-K, Annual Report -
03/14/16 08:58 AMKemPharm Announces FDA Advisory Committee Meeting For Lead Abuse-Deterrent Drug Candidate KP201/APAP - [GlobeNewswire] - CORALVILLE, Iowa, March 14, 2016-- KemPharm, Inc. today announced that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee ...
03/11/16 01:46 PMKemPharm, Inc. Reports Q4 and Year End 2015 Results - GlobeNewswire (press release) - KemPharm, Inc. Reports Q4 and Year End 2015 ResultsGlobeNewswire (press release)CORALVILLE, Iowa, March 10, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today reported its corporate and financial ...
03/10/16 03:03 PMKemPharma reports 4Q loss -
03/10/16 02:50 PMKEMPHARM, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
03/10/16 02:49 PMKemPharm, Inc. Reports Q4 and Year End 2015 Results - [GlobeNewswire] - Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET. Recent Clinical Development& Regulatory Highlights:. Submitted New Drug Application under Section 505 of the Federal Food, Drug ...
03/10/16 01:51 PMAverage Rating Update on KemPharm Inc (NASDAQ:KMPH) - Business Standard Tribune - Average Rating Update on KemPharm Inc (NASDAQ:KMPH)Business Standard TribuneWall Street analysts have an average broker recommendation of 1.25 on KemPharm Inc (NASDAQ:KMPH) shares. The rating is determined by taking the average of all analyst recommendations taken into consideration by Zacks Research.and more »
03/10/16 06:35 AMKemPharm Inc Earnings Call scheduled for 4:30 pm ET today -
03/10/16 06:07 AMQ4 2015 KemPharm Inc Earnings Release - After Market Close -
03/09/16 01:56 PMKemPharm, Inc. (KMPH) New Analyst Updates - Risers & Fallers - KemPharm, Inc. (KMPH) New Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of KemPharm, Inc. (KMPH). According to the latest broker reports outstanding on Monday 7th of March, 2 analysts have a rating of “strong buy”, 2 analysts “buy”, 0 ...
03/09/16 01:56 PMCurrent Price Targets On KemPharm, Inc. (KMPH) - Risers & Fallers - Current Price Targets On KemPharm, Inc. (KMPH)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of KemPharm, Inc. (KMPH). The latest broker reports which are currently outstanding on Wednesday 9th of March state 2 analysts have a rating of “strong buy”, 2 analysts “buy ...
03/08/16 01:55 PMKemPharm Inc Stock Formed Wedge Down Pattern. What To Expect? - RiversideGazette.com - KemPharm Inc Stock Formed Wedge Down Pattern. What To Expect?RiversideGazette.comThe stock of KemPharm Inc (KMPH) formed a down wedge with $13.05 target or 11.00% below today's $14.66 share price. The 8 months wedge indicates high risk for the $197.51M company. If the $13.05 price target is reached, the company will be worth ...
03/07/16 01:43 PMKemPharm Gains 2% – Files IND for Hypromorphone Investigational Prodrug KP511 (NASDAQ:KMPH) - Sonoran Weekly Review - KemPharm Gains 2% – Files IND for Hypromorphone Investigational Prodrug KP511 (NASDAQ:KMPH)Sonoran Weekly ReviewAbout 33,005 shares traded hands. KemPharm Inc (NASDAQ:KMPH) has declined 11.23% since July 30, 2015 and is downtrending. It has underperformed by 6.07% the S&P500. KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers ...KemPharm (KMPH) Announces Filing IND for KP511 with U.S. FDA for Development as Pain TreatmentStreetInsider.comKemPharm Files IND for KP511, an Investigational Prodrug of HydromorphoneEconoTimesall 7 news articles »
About KemPharm

KemPharm logoKemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. It uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs by chemically attaching one or more molecules, referred to as ligands, to the parent drug. Its product candidate, KP201/APAP, is an immediate release (IR) combination of KP201, its prodrug of hydrocodone, and acetaminophen (APAP). It is developing KP201/APAP for the short-term management of acute pain. It is developing KP201/IR (APAP-free) for the short-term management of acute pain. Its product candidates also include KP511/ER and KP606/IR. It is developing KP415 for treatment of attention deficit hyperactivity disorder (ADHD). The Company has not generated any revenue.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KMPH
  • CUSIP:
Key Metrics:
  • Previous Close: $4.15
  • 50 Day Moving Average: $6.07
  • 200 Day Moving Average: $13.65
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $60.76M
  • Current Quarter EPS Consensus Estimate: $-2.79 EPS
Additional Links:
KemPharm (NASDAQ:KMPH) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha